Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver disease, following the U.S. Food and Drug Administration's ...

U.S. stock futures are ticking lower after indexes finished higher for a second straight week. Investors are looking ahead this week to key remarks from Fed Chair Jerome Powell and a string of ...

By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive ...

Investors eyed risks around a high-stakes US-Ukraine meeting, kicking off a week dominated by a Federal Reserve speech that ...

Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk rose nearly 4% on Monday morning, after the company announced that its blockbuster wei ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ: MDGL) stock declined 4% in pre-market trading Monday after the FDA ...